CureVac (CDMO Services)

Tubingen, DE
Hybrid — also manufactures internal programs
mRNA
4 confirmed programs · 1 sponsors · Last scored 2026-03-15
68.0
Signal Score
○ FDA Inspections ✓ Clinical Trials (4) ○ SEC Filings ○ Press

Quick Facts: CureVac (CDMO Services)

Signal Score
68.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Tubingen, DE
Modalities
mRNA
Active CGT Programs
4 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 4
Sponsors1
ModalitiesmRNA
4 active programs across 1 sponsors
Modalities: mRNA
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07073183 Safety and Tolerability of CVHNLC Plus Pembrolizumab in... PHASE1 Not Yet Recruiting
NCT03291002 Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC PHASE1 Unknown
NCT01915524 Trial of RNActive®-Derived Cancer Vaccine and Local Radiation... PHASE1 Terminated
NCT00923312 Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV... PHASE1/PHASE2 Completed
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 83.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Subsidiary of CureVac
SEC FilingsParent: CureVac
Publicly traded — financial transparency
Capacity 53.0
1 CGT manufacturing site: Tubingen, Germany
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: Tubingen, Germany
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Tubingen, Germany
Modalities: mRNA
Capacity assessment: 53.0/100
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →